Skip to main content
  1. Home
  2. Products
  3. Companion Diagnostics
  4. PD-L1 IHC 28-8 pharmDx Non-squamous NSCLC Interpretation Manual

PD-L1 IHC 28-8 pharmDx Non-squamous NSCLC Interpretation Manual

To assess the PD-L1 expression level in patient slides stained with PD-L1 IHC 28-8 pharmDx, pathologists should determine the percentage of viable tumor cells exhibiting partial or complete linear circumferential plasma membrane staining at any staining intensity.

Interpretation Manual

Download non-squamous NSCLC interpretation manual

Contact us for a hard copy of the interpretation manual.

Staining pattern Examples of non-squamous NSCLC Examples of result reporting
< 1% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.

PD-L1 expression < 1%

 PD-L1 expression
< 1%
≥ 1% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.

PD-L1 expression ≥ 1%

 PD-L1 expression
≥ 1%
≥ 5% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.

PD-L1 expression ≥ 5%

 PD-L1 expression
≥ 5%
≥ 10% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.

PD-L1 expression ≥ 10%

 PD-L1 expression
≥ 10%

References

1. PD-L1 IHC 28-8 pharmDx Instruction For Use

Want to hear more about PD-L1 IHC 28-8 pharmDx?

Contact your local sales representative

CONTACT US

Intended Use

For in vitro diagnostic use

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of tumor cells exhibiting positive membrane staining at any intensity.

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO® (nivolumab).

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO® (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered.1